在检测量增加以及预防性健康套餐需求增加的推动下，拉尔病理实验室于周三公布第二季度利润增长超过27%。
Dr Lal PathLabs posted a more than 27% rise in second-quarter profit on Wednesday, helped by higher test volumes and demand for preventive health packages.
截至9月30日的三个月里，这家印度实验室运营商的合并净利润从去年同期的15.1亿卢比增至19.2亿卢比（约合2027万美元）。
该公司股价上涨了3.6%。拉尔病理实验室报告称，该季度合并营业收入同比增长近20%，达到87.4亿卢比。
The Indian lab operator's consolidated net profit for the three months ended September 30 rose to 1.92 billion rupees ($20.27 million), from 1.51 billion rupees a year earlier.
集团首席财务官兼国际业务首席执行官韦德·戈尔表示：“诊断行业继续受益于日益提高的医疗保健意识、预防性健康检查的普及以及印度全国诊断服务渠道的扩大。”
截至3月31日，该公司运营着312家实验室，其在第二季度的检测样本量增加了13.6%。
戈尔表示：“规范化的诊断行业也在经历持续的整合，这为具备强大质量信誉和全国服务网络的规模化企业创造了机遇。”
Shares of the company were up 3.6% Dr Lal reported a near 20% increase in consolidated revenue from operations to 8.74 billion rupees during the quarter "The diagnostics industry continues to benefit from increasing healthcare awareness, rising adoption of preventive health check-ups, and expanding access to diagnostic services across India," said Group Chief Financial Officer and CEO, international business, Ved Goel The company, which operated 312 labs as of March 31, tested 13.6% more samples in the second quarter "The organized diagnostics sector is also witnessing sustained consolidation, creating opportunities for scaled players with strong quality credentials and nationwide reach," Goel said